Table III.
Treatment of patients with FMS-like tyrosine kinase 3-internal tandem duplication mutation mutations.
| Treatment response (%) | Total (n=23) | Mono-chemotherapy (n=16) | Sorafenib plus chemotherapy (n=7) | P-value |
|---|---|---|---|---|
| NR, no. | 5 (21.74) | 5 (31.25) | 0 (0) | 0.039a |
| PR, no. | 3 (13.04) | 2 (12.50) | 1 (14.28) | 0.906 |
| CR, no. | 15 (65.22) | 9 (56.25) | 6 (85.71) | 0.172 |
| OR, no. | 18 (78.26) | 11 (68.75) | 7 (100.00) | 0.039a |
| Relapse, no. | 8 (34.78) | 4 (25.00) | 4 (57.14) | 0.136 |
NR, no response; PR, partial remission; CR, complete remission; OR, overall response.
a
Statistically significant P-value.